Novartis reportedly backs off acquisition of Cytokinetics – WSJ

After Novartis CEO Vas Narasimhan downplayed rumors that his company wanted to acquire the biotech Cytokinetics, the Wall Street Journal reported Thursday that the Big Pharma has backed away from the deal in the last several days.

A representative for Novartis told Endpoints News that the…
Click here to view original post